Abstract:Background: Cyclooxygenase-2 (COX-2) is an inducible enzyme that mediates the synthesis of prostaglandin, which plays an important role in the inflammation response. The overexpression of COX-2 in lung cancer has been found in several studies, suggesting that COX-2 contributes to carcinogenesis. There are many previous case-control studies focused on the association between COX-2 polymorphism and lung cancer risk, however, the conclusion remained controversial. Objectives: We performed this meta-analysis to evaluate the association between COX-2 rs5275 and rs689466 polymorphism and susceptibility to lung cancer. Methods: A systematic literature research was conducted on PubMed, Embase, Cochrane Library, OVID, Web of Science, and Google Scholar up to November 30, 2017. The quality of studies was assessed by Newcastle-Ottawa scale. We combined odds ratios (ORs) and 95% confidence intervals (CIs) in 5 different genetic models for evaluation under a fixed-effect model or random-effect model. Subgroup analysis was performed according to source of control, ethnicity, pathological types, and smoking status. Sensitivity analysis and publication bias were also conducted. Results: Eventually, 14 eligible studies were included in our meta-analysis. We found rs5275 gene polymorphism decreased the risk of lung cancer under heterozygote model (OR: 0.91, 95% CI: 0.84-0.98, P=.02). COX-2 rs689466 gene polymorphism was also related to a significantly reduced risk under allele (OR: 0.88, 95% CI: 0.82-0.95, P=.001), homozygote (OR: 0.81, 95% CI: 0.68-0.95, P=.01), heterozygote (OR: 0.81, 95% CI: 0.72-0.91, P<.001), and dominant model (OR: 0.81, 95% CI: 0.72-0.91, P<.001), except for recessive model. Subgroup analysis suggested a similar association in Asians, but not in Caucasians. Polymorphism of rs5275 was strongly associated with a reduced risk of lung adenocarcinoma according to stratified analysis by pathological types. Egger test identified no significant publication bias. Conclusions: Our meta-analysis demonstrated that COX-2 rs5275 and rs689466 polymorphism significantly decrease the risk of lung cancer in Asians but not in Caucasians, indicating COX-2 could serve as a potential diagnostic marker for lung cancer.

Prognostic Value of Cyclooxygenase-2 Gene Polymorphisms in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy.

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Expression of the cyclooxygenase-2 gene and its clinical significance in non-small cell lung cancer

Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine

Cyclooxygenase-2 Gene Polymorphisms and Susceptibility to Hepatocellular Carcinoma

COX-2 rs 689466 polymorphism correlates with increased lung cancer risk

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

A Novel Single Nucleotide Polymorphism of the Cyclooxygenase-2 Gene Associated with Breast Cancer.

COX-2 Rs5275 and Rs689466 Polymorphism and Risk of Lung Cancer

COX-2 rs5275 and rs689466 polymorphism and risk of lung cancer: A PRISMA-compliant meta-analysis.

Functional Polymorphisms in COX-2 Gene Are Correlated with the Risk of Oral Cancer.

Single Nucleotide Polymorphism in Cyclooxygenase-2 and Its Association with Biological Behavior of Colorectal Cancer

Cyclooxygenase‐2 Gene Polymorphisms Reduce the Risk of Oral Premalignant Lesions

Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population.

Cyclooxygenase-2 Gene Polymorphisms and the Risk of Colorectal Cancer: A Population-Based Study.

PVT1 (rs13281615) and miR‐146a (rs2910164) polymorphisms affect the prognosis of colon cancer by regulating COX2 expression and cell apoptosis

Genetic Variants of BCL2 Gene Predict Clinical Outcomes of Non-Small-cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy in a Chinese Population.

Cyclooxygenase-2 Polymorphisms and Susceptibility to Gastric Carcinoma: A Meta-Analysis

Cox-2 in Non-Small Cell Lung Cancer: A Meta-Analysis

Non-Coding RNA Polymorphisms (rs2910164 and rs1333049) Associated With Prognosis of Lung Cancer Under Platinum-Based Chemotherapy

The Association Between Cyclooxygenase-2 –1195G/A (rs689466) Gene Polymorphism and the Clinicopathology of Lung Cancer in the Japanese Population: A Case-Controlled Study